{
    "clinical_study": {
        "@rank": "13371", 
        "arm_group": {
            "arm_group_label": "Dapsone Gel", 
            "arm_group_type": "Experimental", 
            "description": "Dapsone Gel (Aczone\u00ae) applied twice daily to the face for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the effect of dapsone gel in female subjects with skin of color\n      (Fitzpatrick Skin Types IV, V, and V) with acne vulgaris."
        }, 
        "brief_title": "A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of acne vulgaris\n\n          -  Medium to dark complexion (Fitzpatrick Skin Type IV, V or VI)\n\n          -  Willing to avoid excessive or prolonged exposure of the face to ultraviolet light\n             (eg, sunlight, tanning beds) throughout the study\n\n        Exclusion Criteria:\n\n          -  Received treatment with botulinum toxin of any serotype in the face within 6 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032407", 
            "org_study_id": "GMA-ACZ-13-001"
        }, 
        "intervention": {
            "arm_group_label": "Dapsone Gel", 
            "description": "Dapsone Gel (Aczone\u00ae) applied twice daily to the face for 12 weeks.", 
            "intervention_name": "Dapsone Gel", 
            "intervention_type": "Drug", 
            "other_name": "Aczone\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Dapsone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in the Global Assessment of Acne Severity (GAAS) Score by Physician", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032407"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Lesion Counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage of Subjects with 0 (None) or 1 (Minimal) on the GAAS", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Change from Baseline in the Acne Symptom and Impact Scale (ASIS) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Total Score for the ASIS Symptom Domain", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Total Score for the ASIS Impact Domain", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Change from Baseline in the GAAS", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 2, Week 6"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}